ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.
At two ALK symposia, FlashTalk, oral and poster sessions at the EAACI 2026 scientific programme, ALK will present data on real-world use and clinical implementation of nasal adrenaline in anaphylaxis and share key learnings from 20 years of experience with SLIT tablets.
The two symposia will take place as follows:
Friday 12 June, 12:00-13:00:
From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis.
The symposium will address the unmet needs in paediatric and adult anaphylaxis management, the role of nasal adrenaline, including a presentation of real-world use, patient preference and clinical implementation.
Saturday 13 June, 12:00-13:00:
20 years of SQ SLIT-tablet experience: Key learnings and new horizons
The symposium will address the disease modifying and preventative benefits of allergy immunotherapy, the clinical benefits beyond allergic rhinitis and share efficacy and safety outcomes of a peanut SLIT-tablet phase I/II trial.
Simon Lawton, Global Medical Affairs, Chief medical Office at ALK says:
“We are looking forward to contributing to this year’s EAACI congress where we will showcase the important innovation under way at ALK across anaphylaxis and food allergy. We will also share key insights grounded in robust science and 20 years’ experience with SLIT-tablets. We hope that many EAACI attendees will join our symposia.”
In total, ALK has contributed to 29 abstracts in the scientific programme. Of particular note are additional efficacy and safety findings from clinical trials in adults and children with allergic rhinitis/rhino conjunctivitis treated with SLIT-tablets.
Key highlights of ALK’s contribution include:
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment